Get the Stockscreener App
1.59
0.63%
-0.01
After Hours:
1.59
MAIA Biotechnology Inc stock is traded at $1.59, with a volume of 85,084.
It is down -0.63% in the last 24 hours and down -6.47% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.60
Open:
$1.59
24h Volume:
85,084
Relative Volume:
0.32
Market Cap:
$47.04M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.1522
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
-2.45%
1M Performance:
-6.47%
6M Performance:
-38.85%
1Y Performance:
-31.47%
1-Day Range:
$1.55
$1.6197
1-Week Range:
$1.45
$1.67
52-Week Range:
$1.45
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.59 | 47.04M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener
MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Yahoo Finance
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN
Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? - Insider Monkey
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025 - TipRanks
Q1 EPS Forecast for MAIA Biotechnology Lifted by Analyst - Defense World
MAIA Biotechnology revises offering to $11.2 million By Investing.com - Investing.com Australia
Diamond Equity Comments on MAIA Biotechnology Q1 Earnings - Defense World
MAIA Biotechnology revises offering to $11.2 million - Investing.com
Maia Biotechnology IncDecreases Maximum Aggregate Offering Price To $11.2 MillionSEC Filing - Marketscreener.com
MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - BioSpace
Breakthrough Lung Cancer Drug Shows Exceptional Phase 2 Results: Key Biomarker Discovery - Stock Titan
Maia Bio touts two advances for its lead cancer drug in development - Crain's Chicago Business
MAIA Biotechnology reports breakthrough in cancer treatment research By Investing.com - Investing.com South Africa
MAIA Biotechnology advances with new drug name approval By Investing.com - Investing.com Australia
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - BioSpace
MAIA Biotechnology reports breakthrough in cancer treatment research - Investing.com
Groundbreaking Cancer Drug Breakthrough: THIO Compound Tackles Drug Resistance Head-On - Stock Titan
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - BioSpace
Maia Biotechnology Receives Usan Council Approval For "Ateganosine" As Nonproprietary Name For Anticancer Agent Thio - Marketscreener.com
MAIA Biotechnology advances with new drug name approval - Investing.com
MAIA Biotechnology receives USAN Council approval for ‘Ateganosine’ name - TipRanks
MAIA Biotechnology, Inc. Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO - Marketscreener.com
Major Milestone: MAIA's Novel Lung Cancer Drug Gets Official Name Ateganosine - Stock Titan
MAIA Biotechnology (MAIA) Expected to Announce Earnings on Thursday - Defense World
Maia Biotechnology director Guerrero Ramiro buys $49,999 in stock - Investing.com
MAIA Biotechnology, Inc. to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Marketscreener.com
Maia Biotechnology Plans to Begin Phase 3 Lung Cancer Trial of THIO-104 in H2 -February 27, 2025 at 10:58 am EST - Marketscreener.com
MAIA Biotechnology to initiate THIO-104 trial - TipRanks
Can MAIA's THIO Outperform Chemotherapy in Advanced Lung Cancer? Phase 3 Trial Will Decide - StockTitan
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Business Wire
MAIA Biotechnology Secures $1.43 Million in Non-Brokered Private Placement - Defense World
MAIA Biotechnology announces non-brokered private placement of $1.43M - MSN
MAIA Biotech announces trial design to expand THIO-101 Phase 2 NSCLC study - TipRanks
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology expands phase 2 cancer trial - Investing.com
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer - Yahoo Finance
Maia Biotechnology director Stan Smith acquires $75,000 in stock - Investing.com India
Maia Biotechnology director Stan Smith acquires $75,000 in stock By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million - BioSpace
Can This $4.1M Funding Push MAIA's Cancer Drug Trial to the Next Level? - Stock Titan
MAIA Biotechnology announces $2.7M private placement - MSN
MAIA Biotechnology, Inc. announced that it expects to receive $2.715 million in funding -February 17, 2025 - Marketscreener.com
MAIA Biotechnology Announces Private Placement of $2,715,000 - BioSpace
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Cap:
|
Volume (24h):